Promisng Alzheimer's Disease Drug Dimebon Fails

A promising Alzheimer's disease drug Dimebon worked no better than a placebo in a late-stage study. An unexpected disappointment after Dimebon, the potential blockbuster, stopped Alzheimer’s symptoms from worsening for a year in a prior test. Dimebon, failed to meet its primary and secondary goals improving thinking ability and overall daily function over six months in patients with mild to moderate Alzheimer's disease.

Losing a parent to suicide makes children more likely to die by suicide themselves and increases their risk of developing a range of major psychiatric disorders, according to a study led by Johns Hopkins Children’s Center. The study is believed to be the largest one to date regarding suicide risk of children whose parents committed suicide.

A report on the findings will appear in the May 2010 issue of the Journal of the American Academy of Child & Adolescent Psychiatry.

Adults who used the herbal supplement ginkgo biloba for several years did not have a slower rate of cognitive decline compared to adults who received placebo rather than Ginkgo biloba, according to a recent study published in the Journal of the American Medical Association (JAMA).

Use of this web site constitutes acceptance of the MyBestHealthPortal.com Terms of Service and Privacy Policy. The information on this site is for educational use only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Placement of product information or advertisements does not constitute and endorsement of the products of services described. MyBestHealthPortal.com is a registered trademark of the Behar Health Network.